Login to Your Account

MedImmune, Corixa Take Cases To FDA Advisory Committees

By Kim Coghill

Tuesday, December 17, 2002
While The Street is leaning toward a favorable vote for MedImmune Inc.'s FluMist as an intranasal influenza vaccine, it's not so clear whether Seattle-based Corixa Inc. will get the nod for its cancer drug, Bexxar. (BioWord Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription